triiodothyronine; testosterone; estrogen; protein flux; hemodynamics EUTHYROID SICK SYNDROME was first described nearly three decades ago. Its most prominent feature is a marked decrease in circulating triiodothyronine (T 3 ) levels with the onset of illness or fasting (19) . Recently, a change in terminology from euthyroid sick syndrome to "nonthyroidal illness syndrome" (NTIS) has been adopted by many (8) . This change in nomenclature reflects an underlying controversy as to whether NTIS is truly a euthyroid state or deserves therapy with thyroid hormone (8, 10, 11, 35, 37) . Previous data addressing this question are scant. In some studies, T 3 was administered to patients after coronary artery bypass graft (CABG) surgery or to heart transplant donors and recipients, both of which have NTIS (4, 5, 13, 17, 27, 28, 30, 36) . Mild improvement in cardiac function was reported. However, in most of these studies, supraphysiological doses of T 3 were used for short durations. Another study suggested that NTIS may protect against catabolism in healthy fasting subjects (12) .
To further evaluate the physiological effects of NTIS in the early stages of major illness, we employed a prospective model of patients undergoing CABG, a major surgical procedure that predictably induces NTIS (7, 14, 29) . We monitored selected physiological processes that are known to be altered simultaneously with the onset of NTIS (9, 26, 31) and for which there is established or circumstantial evidence for modulation by T 3 in other settings (16, 18, 23) . These processes included cardiovascular function and protein metabolism, as well as sex steroid, growth hormone (GH) axis, and iron responses to illness. T 3 was infused for 24 h at a dose previously demonstrated to maintain T 3 levels in the midnormal range in an unpublished trial (unpublished observation, SmithKline).
These observations can help further determine whether NTIS is indeed a euthyroid state in acute illness. They can provide additional information regarding questions of benefit (enhanced cardiovascular function) or harm (worsened catabolism) of administering T 3 to patients with NTIS. These questions remain relevant as trials of T 3 in cardiac surgery continue (2, 3) .
METHODS

Patient Population
Fifty-nine patients (7 women and 52 men) undergoing elective CABG were included in the study. Because the primary aim of this study was to evaluate physiological effects of NTIS, volunteers were selected to provide a relatively healthy baseline (with no evidence of NTIS before surgery). We did not intend to answer clinical questions regarding the use of T 3 in patients with markedly compromised preoperative cardiac function. Inclusion criteria were as follows: Յ80 yr of age, ambulatory before surgery with New York Heart Association classification I or II, preoperative ejection fraction Ն40%, no active endocrine illness as assessed by history and by serum levels of thyroxine (T 4), T3, thyroid-stimulating hormone (TSH), testosterone (T), GH, and IGF-I within the normal range before surgery, no major illness other than cardiac disease, and no therapy with thyroid hormone, amiodarone, glucocorticoids, or sex steroids within the past year. Body mass index of patients ranged from 22 to 42. Baseline characteristics of patients are displayed in Table 1 . A single group of five cardiovascular surgeons was involved with similar strategies for postoperative management of patients. The study was approved by the Maine Medical Center Institutional Review Board, and all patients provided written informed consent.
Administration of T3 or Placebo
Patients were randomized in double-blind fashion to treatment or placebo groups. Patients in the T3 group received a bolus dose of 0.2 g/kg at the time of cross-clamp (CC) removal followed by an infusion of 0.8 g/kg over the subsequent 24 h. Placebo was administered in identical infusions. Dosing was selected to maintain serum T 3 levels within the normal range on the basis of an unpublished previous multicenter trial (SmithKline) in which serum levels of T 3 were assessed using bolus doses of 0.1, 0.4, and 0.8 g/kg matched with infusion doses of 0.1, 0.4, and 0.8 g/kg over 6 h after CABG.
Monitoring of Hemodynamics, ECGs, Cardiac Rhythms, and Cardiac Drugs
Cardiac output (CO), mean arterial pressure (MAP), central venous pressure (CVP), and mixed venous O 2 saturation were measured via an indwelling Swan-Ganz catheter upon insertion of the catheter and 1, 6, 12, and 18 h after CC removal. Derivative measurements were cardiac index (CI; calculated as CO Ϭ body surface area) and systemic vascular resistance [calculated as (MAP Ϫ CVP) Ϭ CO].
ECGs were performed just before admission and 36 h after CC removal to monitor heart rate (HR) and evidence of ischemia or myocardial damage. Arrhythmias as recorded by telemetry were monitored for 24 h after CC removal. In addition, in the first 20 patients, cardiac activity was recorded by Holter monitor for the 6 h before CABG and for 24 h after CABG.
Administration of the following classes of drugs was monitored for the 24 h after CC removal: 1) vasodilators (primarily nitrates), 2) inotropes (primarily dopamine), 3) cardiac glycosides, 4) antihypertensives (primarily nitroprusside), 5) ␤-blockers, 6) calcium channel blockers, 7) angiotensin-converting enzyme inhibitors, 8) antiarrhythmics, and 9) diuretics.
Evaluation of Protein Catabolism
Protein metabolism was evaluated in a subset of 20 patients (10 each in placebo and T 3-treated groups). These 20 patients were entered consecutively into the protein protocol during routine recruitment for the larger study. Inclusion criteria were as stated above. Evaluation was accomplished by measurement of urinary nitrogen excretion (U N) and L- [1- 13 C]leucine flux. UN. At 9 h before the start of each leucine infusion, 12-h urine collections were initiated for determination of UN. UN was determined by a macro-Kjeldahl method, but copper sulfate was used as the catalyst (1).
L-[1-
13 C]leucine flux. Leucine tracer kinetics were determined in each patient within 14 days before surgery after a 10-h overnight fast and again 20 -24 h after surgery. At the time of postoperative testing, patients had been without oral intake for 36 h. Any solutions containing dextrose (with the exception of nitroglycerin) were discontinued 3 h before the leucine infusion. L- [1- 13 C]leucine (99% 13 C) was prepared as previously described (24, 25) and infused in a bolus of 2 mol/kg followed by infusion of 2.4 mol ⅐ kg Ϫ1 ⅐ h Ϫ1 for 3 h. Blood samples drawn at 0, 135, 150, 165, and 180 min after administration of the L-[1-
13 C]leucine bolus were placed in iced tubes, and an equal volume of 10% sulfosalicylic acid was added. Plasma was analyzed for ␣-ketoisocaproate (KIC) by gas chromatography-mass spectroscopy (24, 25) . Rate of appearance (R a) or "flux" of leucine into plasma was defined as
where Iiv is the infusion rate of L-[1-13 C] leucine, Eiv is the enrichment of the leucine infused, and Ep is the enrichment of plasma leucine.
Monitoring of Serum Hormone Levels and Iron-Handling Parameters
Concentrations of T3, TSH, total T, GH, IGF-I, and iron, as well as total iron-binding capacity (TIBC), were measured on serum samples obtained from patients within the week before surgery and then following CC removal after surgery ( Table 2 ). We did not monitor serum levels of T 4, because we and other groups previously reported that serum levels of T4 declined in parallel with T3 (but to a lesser degree) after CABG (7, 14, 33) . We also did not measure serum concentrations of free T or sex hormone-binding globulin, because we and others previously reported that serum levels of free T decreased in parallel with total T after CABG (22, 33) .
Serum levels of T were measured using DPC Coat-a-Count T 125 I kit with all intra-and interassay coefficients of variation (CV) Ͻ10%, except interassay CV of 11% at 2.64 nmol/l and intra-assay CV of 18% at 0.69 nmol/l. T 3 was measured using the Ciba-Corning Magic T3
125 I kit, with intra-and interassay CVs at ϳ20, 50, and 80% binding Ͻ10%. Serum concentrations of estrone (E1) and estradiol (E2) were determined by radioimmunoassay after extraction with cyclohexane and ethyl acetate and purification over a Celite column with CVs as previously described (20, 21) . Serum GH and IGF-I levels were measured using a commercial enzyme-linked immunosorbent assay (Diagnostics Systems Laboratories, Webster, TX). Intraassay CVs for GH were 4.3% (0.70 ng/ml), 4.3% (3.68 ng/ml), and 3.3% (18.76 ng/ml), and interassay CVs were 6.5% (3.34 ng/ml), 6.6% (7.83 ng/ml), and 6.3% (15.24 ng/ml). IGF-I was assayed after extraction. Intra-assay CVs were 7.1% (26.5 ng/ml), 4.5% (48.4 ng/ml), and 6.5% (169.7 ng/ml), and interassay CVs were 8.8% (42.9 ng/ml), 4.8% (132.6 ng/ml), and 6.4% (379.1 ng/ml). Serum iron and TIBC were measured using standard methodology.
Statistics
Repeated-measures ANOVA was used to assess treatment and time effects and the time-treatment interaction. We used the time-treatment interaction as the major test of our hypothesis. Mean TSH values from T 3 and placebo groups were compared using a two-tailed unpaired t-test. In addition, because a post hoc examination of confidence intervals suggested a difference between values in the placebo and 
CC, cross clamp; HD, hemodynamic measurement; PreOp, preoperatively; TSH, thyroid-stimulating hormone; T, testosterone; E1, estrone; E2, estradiol; IGF-I, insulin-like growth factor I; GH, growth hormone; TIBC, total ironbinding capacity. Urinary nitrogen excretion and L-[1-
13 C]leucine flux were measured before and 12-24 h after coronary artery bypass graft. treatment groups at 6 h after CC removal, these values were compared using a two-tailed paired t-test.
RESULTS
Serum T 3 and TSH Concentrations
Figure 1 displays serum T 3 concentrations throughout the study in the placebo and T 3 groups. As anticipated, serum T 3 levels decreased markedly in the placebo group but remained at baseline levels in the T 3 group until discontinuation of the infusion at 24 h. TSH remained within the normal range in all patients in the placebo group at 24 h after surgery [1.81 Ϯ 0.22 (0.43-3.84) U/ml]. TSH in the T 3 group was 0.57 Ϯ 0.07 (0.19 -1.18) U/ml, with values slightly below the lower limit of normal (0.4 U/ml) in seven patients. TSH was significantly lower in the T 3 than in the placebo group (P Ͻ 0.0001).
Hemodynamic Parameters
CI was increased over baseline values by 1 h after CC removal in the placebo and T 3 groups ( Fig. 2 ; P Ͻ 0.001). No significant difference in mean CI values was observed between the two groups, except at 6 h after CC removal, when CI in the placebo group fell below CI in the T 3 group (2.53 Ϯ 0.08 vs. 3.04 Ϯ 0.12 l⅐ min Ϫ1 ⅐m
Ϫ2
, P ϭ 0.0016). Values for systemic vascular resistance and mixed venous O 2 saturation were also equivalent in the placebo and T 3 groups (Table 3) . ECG data demonstrated similar increases in HR after CABG in the placebo (19.2 Ϯ 2.9 beats/min) and T 3 (22.4 Ϯ 2.1 beats/min) groups. Holter monitor data confirmed this finding, with increases in HR of 24.8 Ϯ 2.3 and 27.6 Ϯ 2.5 beats/min in the placebo and T 3 groups (P ϭ 0.43). ECG data also demonstrated no ischemic damage in either group.
Arrhythmias and Drug Administration
No differences in the incidence of arrhythmias were noted postoperatively between the placebo and T 3 groups. Particularly, no decrease in the incidence of atrial fibrillation was observed in the T 3 group.
Very few patients in these populations received dopamine. T 3 and placebo patients were equally likely to receive dopamine, and only small "renal" doses (Յ5 g⅐kg Ϫ1 ⅐h Ϫ1 ) were administered. Placebo and T 3 patients were also equally likely to receive 1) vasodilators, 2) inotropes, 3) cardiac glycosides, 4) antihypertensives (primarily nitroprusside), 5) ␤-blockers, 6) calcium channel blockers, 7) angiotensin-converting enzyme inhibitors, 8) antiarrhythmics, and 9) diuretics. 
Sex Steroids
T decreased profoundly in the placebo and T 3 groups to similar nadir levels within the range of prepubertal values (Fig. 4A) . In the placebo group, serum T decreased from a preoperative value of 3.5 Ϯ 0.9 ng/ml to a nadir postoperative value of 0.9 Ϯ 0.4 ng/ml (P Ͻ 0.0001) and in the T 3 group from 4.0 Ϯ 1.4 to 0.8 Ϯ 0.3 ng/ml (P Ͻ 0.0001). These decreases were statistically the same for both groups (P ϭ 0.11).
In contrast to T, serum E 1 levels rose in the placebo and T 3 groups (Fig. 4B) . The increase in the T 3 group (from 34.7 Ϯ 2.6 to 90.9 Ϯ 9.0 pg/ml) was not significantly greater than the increase in the placebo group (from 35.3 Ϯ 3.0 to 70.2 Ϯ 9.1 pg/ml, P ϭ 0.31). Serum levels of E 2 did not rise significantly in either group, with similar values observed in both groups (Table 4) .
GH Axis and Serum Iron and TIBC
Serum GH levels increased and IGF-I levels decreased in placebo and T 3 patients (Table 5) . No significant differences between these changes were observed between the two groups Values are means Ϯ SE in pg/ml. (P ϭ 0.49 and P ϭ 0.40 for GH and IGF-I, respectively). The decrease in the GH/IGF-I ratio was also equivalent in both populations (P ϭ 0.30). Decreases in serum iron concentrations and TIBC were observed after CABG (Table 6 ). No statistical difference was observed in changes in iron (P ϭ 0.49) or TIBC (P ϭ 0.40) between the placebo and the T 3 group.
DISCUSSION
These data demonstrate that preventing the decrease in T 3 during the early stages of NTIS in acute illness has minimal effects on the physiological processes evaluated in our study; there was only a slight transient enhancement in cardiac function. No effect on protein metabolism was evident. Similarly, we observed no evidence of NTIS modulation of the sex steroid, GH-IGF-I axis, or iron responses to acute illness. Thus, although NTIS does not appear to be an entirely euthyroid state, in at least this circumstance (early stages of major illness of moderate severity), physiological effects appear to be minimal. Whether this is true for less healthy patients or for more extended illnesses has yet to be determined.
With respect to cardiac function, one previous study in which a T 3 dose similar to that in this study was used also reported a mild inotropic effect reflected by increased CI and decreased use of dopaminergic agents (28) . Other studies in which much higher doses were used for a 6 h still reported only minimal increases in CI (4, 17) . Thus it is reasonable to assume that any hypothyroid effect of NTIS on cardiovascular function is minimal. The therapeutic effects of T 3 supplementation appear to be clinically inconsequential, particularly compared with standard inotropic agents such as dopaminergic drugs.
With respect to protein metabolism, we did not confirm the previous study suggesting that NTIS is protective against catabolism (12) . That study employed a model of fasting in seven healthy subjects, rather than acute illness. The dose of T 3 resulted in T 3 levels slightly above baseline and suppressed TSH values, indicating that a mildly hyperthyroid state may have been induced. Only urinary urea nitrogen excretion was monitored, rather than the more sophisticated parameters of U N and L- [1- 13 C]leucine flux that are now available. In our study, we were able to maintain serum T 3 concentrations at preoperative levels. TSH remained within the normal range or minimally suppressed, with a lower mean TSH value in the T 3 than in the placebo group. No trend in increased protein catabolism (measured by U N or L-[1-
13 C]leucine flux) was evident in our T 3 patients compared with placebo patients. Therefore, it is unlikely that a larger study of similar patients would reveal a protective effect of NTIS on protein catabolism in the early stages of illness. Whether results with illness of greater severity or longer duration would differ was not addressed by the present study.
The lack of any discernable effect of T 3 administration on other endocrine responses to acute illness rules against a role of NTIS in modulating those responses. The decrease in serum T and rise in E 1 were not different between the T 3 and placebo groups. Thus the hypogonadotropism and decreased testicular responsiveness to luteinizing hormone (6, 22, 32, 33) seem to occur independently from NTIS. Nor does the increased aromatase activity that results in rising estrogen production with acute illness (34) appear to be blunted by NTIS. Similarly, we found no evidence that increased pituitary GH secretion, decreased hepatic responsiveness to GH, or iron handling is affected by NTIS.
Our data indicate that T 3 supplementation is safe with respect to protein catabolism, cardiac arrhythmias, and myocardial ischemia after successful CABG. However, they also argue against continued trials of T 3 therapy in CABG patients because of the lack of discernable benefits. A similar lack of benefit has been observed in children undergoing cardiac surgery (5) . It is possible that a trial including only CABG patients with clearly compromised cardiac function postoperatively may demonstrate a clinical benefit. Until such results are available, T 3 therapy should not be used in CABG patients. Results in transplant donors remain unresolved (15, 27, 30) .
In summary, our data indicate that NTIS with marked decreases of serum T 3 in the early stages of illness is accompanied only by minimal effects of hypothyroidism limited to a transient mild suppression of CI. No effects on protein catabolism, other endocrine responses to acute illness, or iron parameters were observed. The consistent onset of NTIS with illness is suggestive of an adaptive advantage at some point in evolution. Possibly NTIS was of greater importance in settings of marginal nutrition where humans lived (or live) on the edge of a catabolic state. Thus future studies of patients who are more nutritionally compromised before and during their illnesses may be of interest. The present data do not clearly indicate that NTIS is accompanied by significant physiological hypothyroid effects.
